Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer.
$1.28+1.59%
报价 2026-11-06
市值
$340.7M
EV
$588.1M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -49.6%
$1.21$2.54
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AUTLAutolus Therapeutics plc | $340.7M | +1.6% | – | 15.7% | – | – | – | |
| ALLOAllogene Therapeutics, Inc. | $359.3M | -4.6% | – | 0% | – | – | – | |
| IRDOpus Genetics, Inc. | $347.8M | +4.4% | -1.5% | 99.9% | – | – | – | |
| AVIRAtea Pharmaceuticals, Inc. | $345.7M | +2.1% | -19.7% | 0% | – | – | – | |
| FENCFennec Pharmaceuticals Inc. | $344M | +4.5% | +47.4% | 92.2% | – | – | – | |
| OBIOOrchestra BioMed Holdings, Inc. | $341.4M | +1.1% | -54.3% | 99.3% | – | – | – | |
| ALECAlector, Inc. | $339.5M | +9.6% | -64.5% | 100% | – | – | – | |
| CTNMContineum Therapeutics, Inc. Class A Common Stock | $336.6M | +8.1% | +15.0% | 0% | – | – | – | |
| BNTCBenitec Biopharma Inc. | $332.8M | +10.4% | +43.3% | 0% | – | – | – | |
| 同行中位数 | – | – | -1.5% | 46.1% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。